Opendata, web and dolomites

ADHERE TERMINATED

Aptamer nanostructures dual-targeted to the HER receptor family for cancer therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ADHERE project word cloud

Explore the words cloud of the ADHERE project. It provides you a very rough idea of what is the project "ADHERE" about.

resistance    advantageous    extensive    disadvantages    receptors    her1    position    institutes    perspectives    ligands    bispecific    positioned    gain    form    dna    netherlands    aptamers    oligonucleotides    antigens    bioengineering    24    physicochemical    outcome    receive    time    stranded    groningen    immunotherapy    university    wp1    integrate    adhere    vitro    training    multivalent    fashion    reducing    deals    egfr    members    world    therapy    drug    expressing    host    fellowship    young    scientist    multiple    transferable    her2    receptor    cell    me    cells    career    directed    immunoglobulins    aptamer    nanostructures    clinical    chemistry    dual    superior    executed    science    therapeutics    alternative    encompasses    materials    skills    strategy    additional    bind    vivo    strengthen    single    binding    msca    anti    wp2    nanomaterials    polymer    molecule    background    wp3    zernike    cellular    material    myself    types    valuable    cancer   

Project "ADHERE" data sheet

The following table provides information about the project.

Coordinator
RIJKSUNIVERSITEIT GRONINGEN 

Organization address
address: Broerstraat 5
city: GRONINGEN
postcode: 9712CP
website: www.rug.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.rug.nl/research/zernike/polymer-chemistry-and-bioengineering/crielaard-group/
 Total cost 177˙598 €
 EC max contribution 177˙598 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2016
 Duration (year-month-day) from 2016-03-01   to  2018-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RIJKSUNIVERSITEIT GRONINGEN NL (GRONINGEN) coordinator 177˙598.00

Map

 Project objective

The proposed research programme deals with the development of aptamer nanostructures for targeted cancer therapy. Immunotherapy encompasses a growing field of anti-cancer therapeutics that target cancer cells expressing specific antigens, such as members of the HER receptor. Currently, immunoglobulins directed to HER1, better known as EGFR, and HER2 are used in the clinical management of several types of cancer. There are, however, several disadvantages associated with the production and application of immunoglobulins. Moreover, there is evidence that dual-targeting of multiple receptors at the same time is advantageous for improving clinical outcome and reducing drug resistance. Aptamers, which are short single-stranded oligonucleotides that can bind a target molecule in a similar fashion as immunoglobulins, may form, due to their physicochemical properties, a superior alternative strategy for targeted cancer therapy. In ADHERE, I will design (WP1) and investigate in vitro (WP2) and in vivo (WP3) the use of aptamer nanostructures with bispecific (against both EGFR and HER2) and multivalent (up to 4 binding ligands) targeting properties for cancer cell targeting. The 24-month research project will be executed at the department of Polymer Chemistry and Bioengineering at the Zernike Institute for Advanced Materials, University of Groningen, The Netherlands. The aim of this MSCA IF fellowship is to integrate my extensive background in targeted drug delivery and cellular therapeutics within the host institute, which is highly experienced with DNA nanomaterials and is positioned among the top 10 institutes of the world in the field of material science. Importantly, this fellowship will strengthen my career perspectives, by allowing me to gain valuable new transferable skills and receive additional high-level training. This will enable me to position myself as a leading young scientist in the field of clinical nanomaterials.

 Publications

year authors and title journal last update
List of publications.
2017 Bart J. Crielaard, Twan Lammers, Stefano Rivella
Targeting iron metabolism in drug discovery and delivery
published pages: 400-423, ISSN: 1474-1776, DOI: 10.1038/nrd.2016.248
Nature Reviews Drug Discovery 16/6 2019-06-13

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADHERE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ADHERE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

RipGEESE (2020)

Identifying the ripples of gene regulation evolution in the evolution of gene sequences to determine when animal nervous systems evolved

Read More  

SSHelectPhagy (2019)

Regulation of Selective autophagy by sulfide through persulfidation of protein targets.

Read More  

GrowthDevStability (2020)

Characterization of the developmental mechanisms ensuring a robust symmetrical growth in the bilateral model organism Drosophila melanogaster

Read More